» Articles » PMID: 38999328

Advancements in Predictive Tools for Primary Graft Dysfunction in Liver Transplantation: A Comprehensive Review

Overview
Journal J Clin Med
Specialty General Medicine
Date 2024 Jul 13
PMID 38999328
Authors
Affiliations
Soon will be listed here.
Abstract

Orthotopic liver transplantation stands as the sole curative solution for end-stage liver disease. Nevertheless, the discrepancy between the demand and supply of grafts in transplant medicine greatly limits the success of this treatment. The increasing global shortage of organs necessitates the utilization of extended criteria donors (ECD) for liver transplantation, thereby increasing the risk of primary graft dysfunction (PGD). Primary graft dysfunction (PGD) encompasses early allograft dysfunction (EAD) and the more severe primary nonfunction (PNF), both of which stem from ischemia-reperfusion injury (IRI) and mitochondrial damage. Currently, the only effective treatment for PNF is secondary transplantation within the initial post-transplant week, and the occurrence of EAD suggests an elevated, albeit still uncertain, likelihood of retransplantation urgency. Nonetheless, the ongoing exploration of novel IRI mitigation strategies offers hope for future improvements in PGD outcomes. Establishing an intuitive and reliable tool to predict upcoming graft dysfunction is vital for early identification of high-risk patients and for making informed retransplantation decisions. Accurate diagnostics for PNF and EAD constitute essential initial steps in implementing future mitigation strategies. Recently, novel methods for PNF prediction have been developed, and several models for EAD assessments have been introduced. Here, we provide an overview of the currently scrutinized predictive tools for PNF and EAD evaluation strategies, accompanied by recommendations for future studies.

References
1.
Lai Q, Melandro F, Nowak G, Nicolini D, Iesari S, Fasolo E . The role of the comprehensive complication index for the prediction of survival after liver transplantation. Updates Surg. 2020; 73(1):209-221. PMC: 7889667. DOI: 10.1007/s13304-020-00878-4. View

2.
Kwong A, Kim W, Lake J, Smith J, Schladt D, Skeans M . OPTN/SRTR 2018 Annual Data Report: Liver. Am J Transplant. 2020; 20 Suppl s1:193-299. DOI: 10.1111/ajt.15674. View

3.
Park P, Yu Y, Yoon Y, Kim S, Kim D . Single-Center Experience Using Marginal Liver Grafts in Korea. Transplant Proc. 2018; 50(4):1147-1152. DOI: 10.1016/j.transproceed.2018.01.040. View

4.
Yoshino O, Wong B, Cox D, Lee E, Hepworth G, Christophi C . Elevated levels of circulating mitochondrial DNA predict early allograft dysfunction in patients following liver transplantation. J Gastroenterol Hepatol. 2021; 36(12):3500-3507. DOI: 10.1111/jgh.15670. View

5.
Avolio A, Franco A, Schlegel A, Lai Q, Meli S, Burra P . Development and Validation of a Comprehensive Model to Estimate Early Allograft Failure Among Patients Requiring Early Liver Retransplant. JAMA Surg. 2020; 155(12):e204095. PMC: 7593884. DOI: 10.1001/jamasurg.2020.4095. View